生命科学资讯
生物技术与制药领域的最新动态
Moderna faces setback in Arbutus' mRNA patent fight
Illumina To Webcast Upcoming Investor Conference - cnhinews.com
细胞疗法公司拟募资9200万美元,有望终结东京生物科技IPO荒。
Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering
勃林格殷格翰在审查囊性纤维化数据后停止吸入基因疗法研发。
Boehringer axes inhaled gene therapy after viewing cystic fibrosis data
解锁健康数据
Unlocking health data
序列到物质:mRNA疗法的制造之路
Sequence to Substance: Making the mRNA Therapeutic
Appointments and advancements for Feb. 17, 2026
Financings for Feb. 17, 2026
In the clinic for Feb. 17, 2026
Other news to note for Feb. 17, 2026
Regulatory actions for Feb. 17, 2026
康帕斯凭借三期试验成果,准备向FDA提交裸盖菇素申请。
Compass, with Phase 3 hits, ready to take psilocybin to the FDA
10x Genomics (TXG) 股价下跌5.4%,因提交储架发行申请及对2026年展望谨慎——发生了什么变化?
10x Genomics (TXG) Is Down 5.4% After Shelf Offer Filing And Cautious 2026 Outlook What's Changed - simplywall.st
FDA拒绝Disc Medicine罕见病药物,尽管已授予其专员凭证。
FDA rejects Disc Medicine's rare disease drug despite granting it a commissioner voucher
Ocular公司眼药数据告捷,股价却意外下挫。
Ocular claims a win with eye drug data even as shares sink
细胞外基质感知调控肿瘤内自噬通量的异质性
Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux
单细胞时间序列图谱揭示内皮细胞胚胎发育过程
A single-cell time-series atlas of endothelial cell embryonic development
赛诺菲与梯瓦合作研发的IBD药物长期数据展现"关键机遇"。
Sanofi points to 'key opportunity' for Teva-partnered IBD in long-term data
指南针引领迷幻疗法在抑郁症治疗中取得第二项关键性胜利,推动审批进程加速。
Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push